SGMO : Summary for Sangamo Therapeutics, Inc. - Yahoo Finance

U.S. Markets closed

Sangamo Therapeutics, Inc. (SGMO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.05-0.20 (-4.71%)
At close: 4:00PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close4.25
Bid3.25 x 100
Ask4.90 x 1000
Day's Range4.05 - 4.30
52 Week Range2.65 - 7.60
Avg. Volume577,641
Market Cap287.04M
PE Ratio (TTM)-3.99
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube5 days ago

    Sangamo Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SGMO-US : April 18, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sangamo Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Capital Cube16 days ago

    ETFs with exposure to Sangamo Therapeutics, Inc. : April 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sangamo Therapeutics, Inc. Here are 5 ETFs with the largest exposure to SGMO-US. Comparing the performance and risk of Sangamo Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswire25 days ago

    Sangamo Therapeutics Announces Presentation of New Data Demonstrating Significant Reduction of Tau Expression Using Proprietary ZFP Gene Regulation Technology

    RICHMOND, Calif., March 29, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), the leader in therapeutic genome editing, announced today the presentation of new human in vitro and animal model data demonstrating significant reduction of tau mRNA and tau protein expression using the Company's zinc finger protein transcription factor (ZFP-TF)-mediated gene regulation technology. The data were presented by Sangamo's collaborators from Massachusetts General Hospital Alzheimer's Disease Research Center and Harvard Medical School at the 13th International Conference on Alzheimer's & Parkinson's Diseases. "Tau protein plays a critical role in certain devastating neurodegenerative diseases, including dementias such as Alzheimer's disease, and studies point to the potential for tau reduction to prevent neuronal loss and possibly even reverse Alzheimer's disease pathology," said Bradley Hyman, M.D., Ph.D., Director, Massachusetts Alzheimer's Disease Research Center and Alzheimer's Unit Director, MassGeneral Institute for Neurodegenerative Disease at Massachusetts General Hospital, and John B. Penney Jr., Professor of Neurology, Harvard Medical School.